237 active trials 113 recruiting 106 Phase 3 45 disease areas 134 changes in 30 days
75 trials changed in the last 30 days: 1 stopped, 24 with notable changes, 50 with minor changes only.
Withdrawn before enrolling
Sponsor's reason: Business Reasons
Merck Sharp & Dohme LLCPhase 2 NCT07224477 Registry history of NCT07224477 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Apr 1, 2031 to Oct 1, 2031
Merck Sharp & Dohme LLCPhase 1/2 NCT06863272 Registry history of NCT06863272 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Oct 25, 2028 to Mar 7, 2031
Merck Sharp & Dohme LLCPhase 1/2 NCT06818643 Registry history of NCT06818643 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Dec 27, 2029 to Nov 18, 2032
Merck Sharp & Dohme LLCPhase 2 NCT04924075 Registry history of NCT04924075 on ClinicalTrials.gov (opens the registry)
Updated
Primary endpoint(s) modified
Also in this update: Completion pushed from Apr 30, 2029 to Apr 30, 2030
Merck Sharp & Dohme LLCPhase 2 NCT07033494 Registry history of NCT07033494 on ClinicalTrials.gov (opens the registry)
Updated
Primary endpoint(s) modified
Also in this update: Enrollment reduced: 600 → 348 participants; Primary completion moved earlier from Feb 19, 2029 to Jan 24, 2028
Merck Sharp & Dohme LLCPhase 3 NCT06345729 Registry history of NCT06345729 on ClinicalTrials.gov (opens the registry)
Updated
Primary endpoint(s) modified
Also in this update: Enrollment increased: 81 → 181 participants; Trial arms changed: 3 → 4
Merck Sharp & Dohme LLCPhase 1/2 NCT06686394 Registry history of NCT06686394 on ClinicalTrials.gov (opens the registry)
Updated
Primary endpoint(s) modified
Merck Sharp & Dohme LLCPhase 3 NCT06312176 Registry history of NCT06312176 on ClinicalTrials.gov (opens the registry)
Updated
Primary endpoint(s) modified
Merck Sharp & Dohme LLCPhase 3 NCT06136650 Registry history of NCT06136650 on ClinicalTrials.gov (opens the registry)
Updated
Primary endpoint(s) modified
Also in this update: Trial sites expanded: 181 → 362 locations; Interventions modified
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 3 NCT07159763 Registry history of NCT07159763 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Also in this update: Trial sites expanded: 0 → 4 locations
Merck Sharp & Dohme LLCPhase 2 NCT07785609 Registry history of NCT07785609 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Merck Sharp & Dohme LLCPhase 2 NCT07700758 Registry history of NCT07700758 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
And 2 more changes in the last 30 days
Merck Sharp & Dohme LLCPhase 3 NCT07705607 Registry history of NCT07705607 on ClinicalTrials.gov (opens the registry)
Updated
Reclassified as terminated (was completed)
Sponsor's reason: The study stopped due to futility
Merck Sharp & Dohme LLCPhase 3 NCT03833167 Registry history of NCT03833167 on ClinicalTrials.gov (opens the registry)
Updated
Reclassified as terminated (was completed)
Sponsor's reason: The study stopped due to futility
Merck Sharp & Dohme LLCPhase 3 NCT04191096 Registry history of NCT04191096 on ClinicalTrials.gov (opens the registry)
Updated
Reclassified as terminated (was completed)
Sponsor's reason: The study stopped due to futility
Merck Sharp & Dohme LLCPhase 3 NCT03834493 Registry history of NCT03834493 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Merck Sharp & Dohme LLCPhase 2/3 NCT07722611 Registry history of NCT07722611 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Also in this update: Trial sites expanded: 0 → 3 locations; Start date changed from estimate of Sep 22, 2026 to Sep 18, 2026
Merck Sharp & Dohme LLCPhase 3 NCT07776691 Registry history of NCT07776691 on ClinicalTrials.gov (opens the registry)
Updated
Reclassified as terminated (was completed)
Sponsor's reason: Business Reasons
Merck Sharp & Dohme LLCPhase 3 NCT04738487 Registry history of NCT04738487 on ClinicalTrials.gov (opens the registry)
Updated
Reclassified as terminated (was completed)
Sponsor's reason: Business Reasons
Merck Sharp & Dohme LLCPhase 2 NCT04191135 Registry history of NCT04191135 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Merck Sharp & Dohme LLCPhase 3 NCT07218029 Registry history of NCT07218029 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Study completion date changed from estimate of Oct 14, 2026 to Aug 24, 2026
Merck Sharp & Dohme LLCPhase 3 NCT04956692 Registry history of NCT04956692 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
And 1 more change in the last 30 days
Merck Sharp & Dohme LLCPhase 1 NCT07677163 Registry history of NCT07677163 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Merck Sharp & Dohme LLCPhase 1/2 NCT06596694 Registry history of NCT06596694 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Primary completion pushed from Dec 2026 to Mar 1, 2027; Completion moved earlier from Jun 2027 to Mar 1, 2027
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAPhase 2 NCT05270525 Registry history of NCT05270525 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Merck Sharp & Dohme LLCPhase 3 NCT07013487 Registry history of NCT07013487 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Merck Sharp & Dohme LLCPhase 3 NCT06077760 Registry history of NCT06077760 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Merck Sharp & Dohme LLCPhase 3 NCT07044297 Registry history of NCT07044297 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Merck Sharp & Dohme LLCPhase 2 NCT06788912 Registry history of NCT06788912 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Final enrollment: 263 participants (planned 370)
Merck Sharp & Dohme LLCPhase 1/2 NCT04626518 Registry history of NCT04626518 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Merck Sharp & Dohme LLCPhase 1/2 NCT04626479 Registry history of NCT04626479 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Study completion date changed from estimate of Oct 4, 2026 to Aug 25, 2026
Merck Sharp & Dohme LLCPhase 2 NCT04489771 Registry history of NCT04489771 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Merck Sharp & Dohme LLCPhase 2 NCT06465186 Registry history of NCT06465186 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Merck Sharp & Dohme LLCPhase 1 NCT07405177 Registry history of NCT07405177 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Merck Sharp & Dohme LLCPhase 1 NCT07619443 Registry history of NCT07619443 on ClinicalTrials.gov (opens the registry)
Updated
Trial status changed: Not Yet Recruiting → Active, Not Recruiting
Merck Sharp & Dohme LLCPhase 1 NCT07748351 Registry history of NCT07748351 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Merck Sharp & Dohme LLCPhase 1 NCT07300280 Registry history of NCT07300280 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Merck Sharp & Dohme LLCPhase 1 NCT07388667 Registry history of NCT07388667 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Merck Sharp & Dohme LLCPhase 1 NCT07776665 Registry history of NCT07776665 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Merck Sharp & Dohme LLCPhase 1 NCT07242469 Registry history of NCT07242469 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Final enrollment: 18 participants (planned 24)
Merck Sharp & Dohme LLCPhase 1 NCT07348237 Registry history of NCT07348237 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Nov 6, 2026 to Feb 12, 2027
Merck Sharp & Dohme LLCPhase 2 NCT03407144 Registry history of NCT03407144 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Jan 14, 2034 to Apr 22, 2034
Merck Sharp & Dohme LLCPhase 3 NCT07405164 Registry history of NCT07405164 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Sep 15, 2026 to Nov 20, 2026
Merck Sharp & Dohme LLCPhase 3 NCT04634877 Registry history of NCT04634877 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 104 → 117 locations
And 3 more changes in the last 30 days
Merck Sharp & Dohme LLCPhase 3 NCT07513376 Registry history of NCT07513376 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 18 → 23 locations
And 3 more changes in the last 30 days
Merck Sharp & Dohme LLCPhase 3 NCT07705555 Registry history of NCT07705555 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 91 → 95 locations
And 4 more changes in the last 30 days
Merck Sharp & Dohme LLCPhase 3 NCT07554339 Registry history of NCT07554339 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 26 → 32 locations
Merck Sharp & Dohme LLCPhase 2/3 NCT07634471 Registry history of NCT07634471 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 177 → 180 locations
And 1 more change in the last 30 days
Merck Sharp & Dohme LLCPhase 3 NCT07216703 Registry history of NCT07216703 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 41 → 46 locations
Merck Sharp & Dohme LLCPhase 1/2 NCT07519772 Registry history of NCT07519772 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 95 → 104 locations
And 1 more change in the last 30 days
Merck Sharp & Dohme LLCPhase 3 NCT07419295 Registry history of NCT07419295 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 311 → 314 locations
Merck Sharp & Dohme LLCPhase 3 NCT06393374 Registry history of NCT06393374 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 92 → 99 locations
Merck Sharp & Dohme LLCPhase 3 NCT07489495 Registry history of NCT07489495 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 79 → 84 locations
And 2 more changes in the last 30 days
Merck Sharp & Dohme LLCPhase 3 NCT05947851 Registry history of NCT05947851 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 0 → 4 locations
Also in this update: Start date pushed from Sep 29, 2026 to Oct 27, 2026
Merck Sharp & Dohme LLCPhase 2 NCT07793942 Registry history of NCT07793942 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 215 → 218 locations
And 2 more changes in the last 30 days
Merck Sharp & Dohme LLCPhase 3 NCT07190248 Registry history of NCT07190248 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 239 → 243 locations
Merck Sharp & Dohme LLCPhase 3 NCT06997497 Registry history of NCT06997497 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 106 → 110 locations
And 2 more changes in the last 30 days
Merck Sharp & Dohme LLCPhase 3 NCT07431827 Registry history of NCT07431827 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 66 → 70 locations
And 2 more changes in the last 30 days
Merck Sharp & Dohme LLCPhase 2 NCT07614984 Registry history of NCT07614984 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 275 → 278 locations
And 1 more change in the last 30 days
Merck Sharp & Dohme LLCPhase 3 NCT06717347 Registry history of NCT06717347 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 35 → 38 locations
And 1 more change in the last 30 days
Merck Sharp & Dohme LLCPhase 2 NCT07463183 Registry history of NCT07463183 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 54 → 63 locations
Merck Sharp & Dohme LLCPhase 1/2 NCT06941272 Registry history of NCT06941272 on ClinicalTrials.gov (opens the registry)
Updated
Start date changed from estimate of Sep 25, 2026 to Sep 17, 2026
Merck Sharp & Dohme LLCPhase 2 NCT07646860 Registry history of NCT07646860 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion moved earlier from Apr 27, 2029 to Feb 15, 2029
Merck Sharp & Dohme LLCPhase 1/2 NCT06780137 Registry history of NCT06780137 on ClinicalTrials.gov (opens the registry)
Updated
Completion moved earlier from Aug 31, 2028 to Jun 1, 2027
Also in this update: Primary completion moved earlier from Aug 27, 2027 to Jan 15, 2027
Merck Sharp & Dohme LLCPhase 3 NCT04199689 Registry history of NCT04199689 on ClinicalTrials.gov (opens the registry)
Updated
Start date pushed from Sep 25, 2026 to Oct 9, 2026
Merck Sharp & Dohme LLCPhase 2 NCT07709000 Registry history of NCT07709000 on ClinicalTrials.gov (opens the registry)
Updated
Interventions modified
Merck Sharp & Dohme LLCPhase 3 NCT07060807 Registry history of NCT07060807 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Apr 3, 2030 to Dec 18, 2031
Also in this update: Primary completion moved earlier from Mar 21, 2029 to Feb 1, 2029
Merck Sharp & Dohme LLCPhase 2/3 NCT07266831 Registry history of NCT07266831 on ClinicalTrials.gov (opens the registry)
Updated
Completion moved earlier from Jul 31, 2029 to Nov 16, 2026
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 2 NCT05270668 Registry history of NCT05270668 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Sep 8, 2026 to Oct 8, 2026
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 1 NCT02974738 Registry history of NCT02974738 on ClinicalTrials.gov (opens the registry)
Updated
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-09 | NCT07867938 A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis… | Phase 2 | Not Yet Recruiting |
| 2026-10-07 | NCT07862569 DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg | Phase 2 | Not Yet Recruiting |
| 2026-10-07 | NCT07862595 A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery… | Phase 2 | Not Yet Recruiting |
| 2026-10-07 | NCT07862621 A Clinical Trial of MK-6916 With Midazolam and Rosuvastatin in Healthy Participants… | Phase 1 | Not Yet Recruiting |
| 2026-10-06 | NCT07861074 A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis… | Phase 2 | Not Yet Recruiting |
| 2026-10-02 | NCT07855510 A Clinical Trial of V175 and V175A in Healthy Adults | Phase 1 | Not Yet Recruiting |
| 2026-09-30 | NCT07850310 A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis… | Phase 1 | Not Yet Recruiting |
| 2026-09-30 | NCT07850609 A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse… | Phase 2 | Not Yet Recruiting |
| 2026-09-24 | NCT07839585 A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and… | Phase 3 | Not Yet Recruiting |
| 2026-09-21 | NCT07829783 A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab… | Phase 3 | Not Yet Recruiting |
| Phase 1 | 35 | |
| Phase 1/2 | 34 | |
| Phase 2 | 58 | |
| Phase 2/3 | 7 | |
| Phase 3 | 99 | |
| Phase 4 | 2 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT07801027 | A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From… | Neoplasm Malignant | Not Yet Recruiting | 2026-09-03 |
| NCT07600723 | A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in… | Pulmonary Arterial Hypertension | Not Yet Recruiting | 2026-08-07 |
| Phase 3 | ||||
| NCT07513376 | A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated… | Non-small Cell Lung Cancer | Recruiting | 2026-10-09 |
| NCT07554339 | A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell… | Non-small Cell Lung Cancer | Recruiting | 2026-10-09 |
| NCT07705555 | A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular… | Diabetic Retinopathy | Recruiting | 2026-10-09 |
| NCT07705607 | A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular… | Diabetic Retinopathy | Recruiting | 2026-10-09 |
| NCT06925737 | A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate… | Prostate Cancer | Recruiting | 2026-10-08 |
| NCT07060807 | A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | Breast Neoplasms | Recruiting | 2026-10-08 |
| NCT03486873 | Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who… | Solid Tumors | Recruiting | 2026-10-07 |
| NCT06345729 | A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS… | Non-small Cell Lung Cancer | Recruiting | 2026-10-07 |
| NCT06997497 | A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People… | Colon Adenocarcinoma | Recruiting | 2026-10-07 |
| NCT07190248 | A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With… | Non-small Cell Lung Cancer | Recruiting | 2026-10-07 |
| NCT07431827 | MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC… | Non-small Cell Lung Cancer | Recruiting | 2026-10-07 |
| NCT06136624 | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | Prostate Cancer Metastatic | Recruiting | 2026-10-06 |
| NCT06136650 | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA)… | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Recruiting | 2026-10-06 |
| NCT06312176 | A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With… | Breast Neoplasms | Recruiting | 2026-10-06 |
| NCT06393374 | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not… | Triple-Negative Breast Cancer | Recruiting | 2026-10-06 |
| NCT06422143 | Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in… | Non-small Cell Lung Cancer | Recruiting | 2026-10-06 |
| NCT06824467 | A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870)… | Ovarian Cancer | Recruiting | 2026-10-06 |
| NCT06841354 | A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination… | Triple Negative Breast Neoplasms | Recruiting | 2026-10-06 |
| NCT06952504 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab… | Endometrial Cancer | Recruiting | 2026-10-06 |
| NCT06966700 | A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast… | Breast Neoplasms | Recruiting | 2026-10-06 |
| NCT07216703 | A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab… | Cervical Cancer | Recruiting | 2026-10-06 |
| NCT07318558 | A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer… | Ovarian Neoplasms | Recruiting | 2026-10-06 |
| NCT07405164 | Extension Study for Participants in Studies That Include Belzutifan… | Von Hippel-Lindau Disease | Recruiting | 2026-10-06 |
Lung Cancer (35) · Non-Small Cell Lung Cancer (NSCLC) (25) · Kidney Cancer (16) · Bladder Cancer (14) · Breast Cancer (10) · Hypertension (8) · Leukemia (8) · Non-Hodgkin Lymphoma (8) · DLBCL (7) · Small Cell Lung Cancer (7)